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Purpose of the study
Treatment of chronic hepatitis C virus (HCV) infection
in HIV-1 co-infected individuals remains challenging
due to numerous factors including drug-drug interac-
tions. The aim of this study was to assess the safety and
pharmacokinetic (PK) profile of raltegravir, a recently
licensed antiretroviral agent, and ribavirin, when dosed
separately and together.
Methods
Fourteen healthy volunteers (mean (standard deviation)
age 35 (10) years, 71% male) entered this phase I PK
study and received single dose ribavirin (800 mg) on day
1( phase 1). Following a wash-out period, subjects
received raltegravir (400 mg twice daily) on days 15-19
(phase 2) and single dose ribavirin (800 mg) with ralte-
gravir (400 mg) on day 20 (phase 3). Intensive PK sam-
pling was undertaken on days 1, 19 and 20 and
differences in geometric mean ratios (GMR) for PK
parameters between study periods assessed.
Results
No statistically significant differences in PK parameters
were observed for raltegravir between phases 2 versus 3.
A statistically significant decrease in maximum plasma
concentration (Cmax) and increase in time to maximum
plasma concentration (Tmax) was observed for ribavirin
in phase 3 compared to phase 1 (GMR (95% CI) 0.79
(0.62 - 1.00) and 1.39 (1.08 - 1.78), respectively; Table 1)
whereas no significant differences in other ribavirin PK
parameters were observed between study phases includ-
ing area under-time-curve (AUC) or minimum observed
plasma concentration (Cmin). No clinically significant
safety concerns were reported.
Conclusions
The PK profile of ribavirin is altered when administered
with raltegravir (reduced Cmax and increased Tmax).
This is unlikely to be of clinical significance or have an
impact on the antiviral effects of ribavirin in HIV-1 and
HCV co-infected subjects.
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Table 1
mean(95% CI) mean(95% CI) GMR (95% CI)
Ribavirin PK parameters phase I (ribavirin alone) phase 3 (ribavirin with raltegravir)
T ½, h 6.04 (5.29 - 6.90) 6.77 (5.56 - 8.25) 1.12 (0.86 - 1.46)
Tmax, h 1.61 (1.12 - 2.11) 2.23 (1.65 - 3.01) 1.39 (1.08 - 1.78)
Cmax, ng/mL 630.09 (490.91 - 808.54) 496.71 (407.38 - 605.76) 0.79 (0.62 - 1.00)
Cmin, ng/mL 184.71 (148.59 - 229.61) 186.98 (157.83 - 221.56) 1.01 (0.87 - 1.18)
AUC0-12 3325.83 (2703.34 - 4091.66) 2941.03 (2323.27 - 3722.20) 0.88 (0.73 - 1.07)
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